Filtered By:
Source: International Journal of Cardiology
Nutrition: Vitamin K
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Non-Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have changed the landscape for stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more attention to stroke prevention is clearly needed. Aiming to provide an overview and reappraisal of stroke prevention in Asians with AF, we searched MEDLINE for information on NOACs in Asians. In addition, abstracts from national and international cardiovascular meetings were studied to identify unpublished studies.In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is evident.
Source: International Journal of Cardiology - November 26, 2014 Category: Cardiology Authors: Gregory Y.H. Lip, Kang-Ling Wang, Chern-En Chiang Tags: Review Source Type: research
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
Non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more attention to stroke prevention is clearly needed. Aiming to provide an overview and reappraisal of stroke prevention in Asians with AF, we searched MEDLINE for information on NOACs in Asians. In addition, abstracts from national and international cardiovascular meetings were studied to identify unpublished studies.In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is evident.
Source: International Journal of Cardiology - November 26, 2014 Category: Cardiology Authors: Gregory Y.H. Lip, Kang-Ling Wang, Chern-En Chiang Tags: Review Source Type: research
Effect of prior anticoagulation therapy on stroke severity and in-hospital outcomes in patients with acute ischemic stroke and atrial fibrillation
We aimed to assess the prevalence of prior anticoagulation therapy (warfarin or non-vitamin K antagonist oral anticoagulants [NOACs]) among patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) in China and investigate the associations between prior anticoagulation therapy and initial stroke severity and in-hospital outcomes.
Source: International Journal of Cardiology - May 29, 2023 Category: Cardiology Authors: Lue Zhou, Yapeng Li, Xin Yang, Hongqiu Gu, Yanran Duan, Hang Fu, Anran Wang, Kai Liu, Yuan Gao, Bo Song, Yusheng Li, Yingyu Jiang, Jing Zhang, Chunjuan Wang, Meng Wang, Zixiao Li, Yuming Xu, Chengzeng Wang, Yongjun Wang Source Type: research
Inadequate anticoagulation by Vitamin K antagonists and major adverse cardiovascular events other than stroke
I read the article by Pastori et al. [1] with great interest. In their artcile, the authors reported that inadequate anticoagulation by Vitamin K Antagonists was found to be associated with Major Adverse Cardiovascular Events (MACE) in patients with atrial fibrillation, and they concluded that time in therapeutic range (TTR) was an independent predictor of MACE in patients with atrial fibrillation. It is known that inadequate anticoagulation by Vitamin K Antagonists is a strong predictor of stroke.
Source: International Journal of Cardiology - October 30, 2015 Category: Cardiology Authors: Mehmet Eyuboglu Tags: Correspondence Source Type: research
Stroke risk assessment in atrial fibrillation: Beyond atrial rhythm
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is responsible for at least 20% of all strokes. Moreover, strokes associated to AF are largely avoidable, as the use of anti-vitamin K drugs can prevent>65% of all strokes, and direct oral anticoagulants con reduce the rate of stroke by a further 19% [1].
Source: International Journal of Cardiology - May 22, 2019 Category: Cardiology Authors: Giovanni Luca Botto, Francesco Maria Brasca Tags: Editorial Source Type: research
Persisting stroke risk in patients with atrial fibrillation despite proper anticoagulation – Unmet clinical needs
Oral anticoagulation (OAC) is crucial to prevent cardioembolic stroke in patients with atrial fibrillation (AF). Development of the direct oral anticoagulants (DOAC), which inhibit activities of the coagulant proteases thrombin and activated factor X (FXs), has improved the safety and efficacy of anticoagulation in AF, compared to traditional vitamin K antagonists like warfarin [1,2]. Yet in a small, but numerically relevant proportion of up to 2% of patients, this cornerstone principle fails for unclear reasons.
Source: International Journal of Cardiology - August 6, 2022 Category: Cardiology Authors: Florian Bruns, Dobromir Dobrev, Anke C. Fender Tags: Editorial Source Type: research
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups
Stroke is the most serious clinical consequence of atrial fibrillation, which is the most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as efficacious, safe and convenient stroke prevention agents. This updated network meta-analysis focused on the relative efficacy and safety of apixaban compared with dabigatran, rivaroxaban and edoxaban for stroke prevention in (i) patients with CHADS2 score ≥2, (ii) secondary stroke prevention, and (iii) patients with high quality anticoagulation control with warfarin.
Source: International Journal of Cardiology - November 17, 2015 Category: Cardiology Authors: Gregory Y.H. Lip, Stephen A. Mitchell, Xianchen Liu, Larry Z. Liu, Hemant Phatak, Sumesh Kachroo, Sarah Batson Source Type: research
Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed
Use of oral anticoagulant (OAC) therapy for stroke prevention is a main aspect of management for patients with atrial fibrillation (AF). Guidelines for the management of AF indicate that OAC is usually needed in patients with at least one stroke risk factor [1]. This has been possibly achieved for a long time using a vitamin K antagonist (VKA). This may also be done for a few years using one of the non-vitamin K oral anticoagulant (NOACs) in case the patient has neither a EHRA (Evaluated Heartvalves, Rheumatic or Artificial) Type 1 valvular AF nor a contraindication to NOAC [2].
Source: International Journal of Cardiology - December 15, 2017 Category: Cardiology Authors: Laurent Fauchier, Arnaud Bisson, Thibaud Genet Tags: Editorial Source Type: research
Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients: A retrospective propensity score matched cohort study
Vitamin K antagonists (VKAs) have been shown to decrease the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). [1] The non-VKA oral anticoagulants (NOACs) are now increasingly used as an alternative to VKAs thanks to their convenient, fixed dose and no requirement for monitoring. NOACs have shown non-inferiority to warfarin for the prevention of stroke and systemic embolism, with marked reduction in the risk of intracerebral haemorrhage [2].
Source: International Journal of Cardiology - April 25, 2018 Category: Cardiology Authors: Giacomo Zoppellaro, Luca Zanella, Gentian Denas, Nicola Gennaro, Eliana Ferroni, Ugo Fedeli, Seena Padayattil Jose, Giorgio Costa, Maria Chiara Corti, Margherita Andretta, Vittorio Pengo Source Type: research
No antiarrhythmic effect of direct oral anticoagulants versus vitamin K antagonists in paroxysmal atrial fibrillation patients undergoing catheter ablation
Direct oral anticoagulants (DOACs) are superior to vitamin K antagonists (VKAs) for the prevention of stroke in atrial fibrillation (AF) patients with elevated stroke risk. Possible antiarrhythmic effects of DOACs have been discussed. We analyzed impact of DOAC treatment on recurrence-free survival after AF catheter ablation.
Source: International Journal of Cardiology - January 25, 2021 Category: Cardiology Authors: David Zweiker, Martin Manninger, Raphael Sieghartsleitner, Jakob Ebner, Bernadette Pratl, Egbert Bisping, Peter Lercher, Dirk von Lewinski, Rita Riedlbauer, Ursula Rohrer, Henri M.H. Spronk, Andreas Zirlik, Ulrich Schotten, Daniel Scherr Tags: Short communication Source Type: research
Percutaneous left atrial appendage closure vs oral anticoagulation: The scariest might be the cheepest
Left Atrial Appendage Closure (LAAC) in patients with atrial fibrillation (AF) and consequent elevated risk of thromboembolic events has an excellent safety profile, with an equal efficacy in preventing stroke, compared with vitamin K antagonists in patients without contraindications to oral anticoagulants [1]. It is also noninferior to direct oral anticoagulants (DOACs) in preventing major AF-related ischemic and haemorrhagic events [2]. Nevertheless, according to the current practice guidelines, percutaneous LAAC is still recommended only in patients with AF at increased risk of stroke and with contraindications to long-term OAC [3,4].
Source: International Journal of Cardiology - January 29, 2022 Category: Cardiology Authors: Patrizio Mazzone, Paolo Della Bella, Francesca Baratto Tags: Editorial Source Type: research
Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists
Although vitamin K antagonists (VKAs) greatly reduce the risk of stroke in non-valvular atrial fibrillation (NVAF), the risk of bleeding with this therapy remains challenging [1]. HAS-BLED [2,3] and ATRIA [4] are currently the most popular scoring systems for bleeding risk assessment in NVAF. Until now, the main studies [5–7] compared both scores used “modified” versions of the original scores, whilst the current recommendation [3] is to use HAS-BLED as it was originally conceived. Furthermore, most of these studies came from trial population or hospitalized patients [5,7].
Source: International Journal of Cardiology - August 7, 2014 Category: Cardiology Authors: Rami Riziq-Yousef Abumuaileq, Emad Abu-Assi, Sergio Raposeiras-Roubin, Andrea López-López, Alfredo Redondo-Diéguez, Diego Álvarez-Iglesias, Moisés Rodríguez-Mañero, Carlos Peña-Gil, Jose Ramón González-Juanatey Source Type: research
Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants
In the controlled clinical trials ROCKET AF and ARISTOTLE, which included patients with nonvalvular atrial fibrillation (AF), introduction of warfarin was associated with an excess of ischemic strokes during the first 30days after randomization in vitamin K antagonist (VKA)-naive patients compared with warfarin-experienced patients (4.40/100 patient-years versus 2.86/100 patient-years in ROCKET AF and 5.41/100 patient-years versus 1.42/100 patient-years in ARISTOTLE) [1]. A similar observation was made in the RE-LY trial, in which the risk of ischemic stroke was 0.26% for warfarin versus 0.12% for dabigatran (odds ratio 2....
Source: International Journal of Cardiology - March 19, 2015 Category: Cardiology Authors: Sébastien Gaertner, Elena-Mihaela Cordeanu, Corina Mirea, Dominique Stephan Tags: Letter to the editor Source Type: research
Meta-analysis of Risk of Stroke and Thrombo-Embolism with Rivaroxaban versus Vitamin K antagonists in ablation and cardioversion of atrial fibrillation
: Anticoagulation in cardioversion and ablation of atrial fibrillation is imperative for reducing thrombo-embolic events. Ample information is available about use of warfarin and vitamin K antagonists (VKA) but few trials examine safety and efficacy of rivaroxaban in these procedures. We aim to explore the hypothesis that rivaroxaban causes equal thrombo-embolic and bleeding events when used in atrial fibrillation patients undergoing ablation or cardioversion compared to VKA.
Source: International Journal of Cardiology - March 25, 2015 Category: Cardiology Authors: Ramez Nairooz, Partha Sardar, Maria Pino, Wilbert S. Aronow, Asif Sewani, Debabrata Mukherjee, Hakan Paydak, Waddah Maskoun Source Type: research
